This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background and Purpose:Whether imaging markers of cerebral small vessel disease on computed tomography (CT-CSVD) relates to early clinical outcomes after intravenous thrombolysis for acute ischemic stroke remains not well understood. 1.02; score 2: OR 0.46, 95%CI 0.26-0.83; 0.83; score 3: OR 0.16, 95%CI 0.03-0.76, 1.95, p = 0.019).Conclusion:This
While DM can reduce the effect of intravenous thrombolysis, metformin can have a positive outcome on AIS patients. The outcomes of stroke in diabetic patients receiving metformin is largely unexplored. There is a trend of favorable outcomes of mRS and Mortality, with a non-statistical significance increase of sICH.
Introduction:Tenecteplase (TNK) is now an accepted alternative to Alteplase (ALT) for intravenous thrombolysis (IVT) in acute ischemic stroke (AIS). Hemorrhagic transformation (HT), a complication of IVT, is more frequent in acute hyperglycemia and diabetes (DM) and is associated with poor clinical outcomes.
Patients were dichotomized into those with 90‐day good functional outcome (modified Rankin scale [mRS] score 0–2) and poor functional outcome (mRS score ≥3). Good functional outcome was observed in 44 patients (40%). P = 0.016), and diabetes (18.2% Baseline and procedural data were compared between the 2 cohorts.
We aimed to examine the impact of dexmedetomidine on outcomes in patients with anterior circulation large vessel occlusion (acLVO) requiring neurocritical care after endovascular therapy (EVT).Methods:We While favorable functional outcome was less frequently observed in the dexmedetomidine than in the comparator group (7.9%
Introduction:In large vessel occlusion (LVO) ischemic stroke patients, better functional outcomes are associated with achieving modified thrombolysis in cerebral infarction (mTICI) score 2C/3 in comparison to 2B. Primary outcome measure was achieving mTICI 2C/3 (i.e., excellent) revascularization. were female.
MVO and IMH are associated with an increased risk of adverse outcome independent of infarct size, but whether the size of the culprit lesion vessel plays a role in the occurrence and severity of reperfusion injury is currently unknown. Median culprit lesion vessel size was 3.1 (2.7–3.6)
For inclusion, patients must have been successfully recanalized by mechanical thrombectomy with or without intravenous thrombolytic and ultimate modified thrombolysis in cerebral infarction (mTICI) score 2B/2C/3. The multivariate model (area under curve = 0.93) had three significant predictors: diabetes mellitus (aOR 36.5,
BACKGROUNDIn patients with acute ischemic stroke secondary to large vessel occlusion, achieving modified Thrombolysis in Cerebral Infarction (mTICI) 2c/3 (excellent recanalization) over mTICI 2b is associated with improved functional outcomes. P=0.036), were less likely to have a history of diabetes (aOR, 0.42;P=0.050)
treatment window for thrombolysis. Patients with missed strokes were more likely female than those with accurate strokes (57% vs 39%, p<0.01), have a history of diabetes (43% vs 26%, p=0.03), and were more likely to receive recommendation for seizure workup (25% vs 8%, p<0.01).
Case submitted and written by Mazen El-Baba MD, with edits from Jesse McLaren and edits/comments by Smith and Grauer A 90-year old with a past medical history of atrial fibrillation, type-2 diabetes, hypertension, dyslipidemia, presented with acute onset chest/epigastric pain, nausea, and vomiting. BP was 110 and oxygen saturation was normal.
These data from the SHINE trial continue to inform the national stroke community about potential approaches to treating hyperglycemic stroke patients to assure better outcomes,” she said. Of the 1,151 SHINE trial participants, 725, or 63%, underwent thrombolysis. Approximately 80% had type 2 diabetes.
Outcomes included sICH, and inpatient mortality, adjusted for confounders which included age, gender, baseline NIHSS, perfusion grade (TICI) intravenous thrombolysis, history of diabetes and HBA1c.Results:A total of 224 patients (mean age was 68.7 years (±14.3); 44.2% were women) underwent endovascular treatment.
IntroductionThe risk of tandem occlusion treatment in the setting of intravenous thrombolysis is unclear. Patients who received thrombolysis and subsequently underwent endovascular therapy for acute ischemic stroke between 2012 and 2022 were included. Baseline demographics and clinical characteristics were compared. vs 55%, p=0.03).
Its insidious nature often occurring without warning has profound implications for patient outcomes, underscoring the need for proactive prevention, rapid response, and advanced treatment strategies. Often called the "silent killer," stroke is a leading cause of death and disability worldwide.
We sought to identify the differential clinical and neuroimaging characteristics, and outcomes in matched AIS cohorts from Norway (NOR) and the United States (US).Methods:AIS Cohorts were matched on age, sex, diabetes, atrial fibrillation, and hypertension. A greater proportion of the US cohort underwent IV thrombolysis (30.7%
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
40 
Let's personalize your content